Case reports of chronic myeloid leukemia and tuberculosis: Is imatinib the link between the two?

作者：S. Verma, A. Tripathi, Nidhish Kumar, Sunil Gupta · 发表于：Indian Journal of Tuberculosis · 年份：2020 · DOI：10.1016/j.ijtb.2020.11.004 · 研究领域：Medicine

Current standard of care for treatment of CML is based on tyrosine kinase inhibitors (TKI's). Imatinib is most frequently used first line tyrosine kinase inhibitor. Various side effects of TKI's are known, but some may still be unknown. We are reporting three cases of CML who developed tuberculosis while on treatment with imatinib or dasatinib. Two cases developed CNS tuberculosis and other one was tubercular pleural effusion. These cases indicate that imatinib and other TKI's probably interfere with immunological functions and predispose patients for tuberculosis.